Sorafenib tosylate for advanced kidney cancer: lucky loser and magic box at the same time
Despite being the very first molecular targeted agents registered for the treatment of advanced kidney cancer (in the post-cytokines setting), Sorafenib seemed to lose its momentum as a credible first-line treatment option, when it proved not to be superior to Interferon within a randomized phase II...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2011-09-01
|
| Series: | Oncology Reviews |
| Online Access: | http://www.oncologyreviews.org/index.php/or/article/view/10 |
| id |
doaj-aefb00e212f6499690bfcbabf172f971 |
|---|---|
| record_format |
Article |
| spelling |
doaj-aefb00e212f6499690bfcbabf172f9712020-11-25T02:25:14ZengPAGEPress PublicationsOncology Reviews1970-55571970-55652011-09-015310.4081/oncol.2011.1416Sorafenib tosylate for advanced kidney cancer: lucky loser and magic box at the same timeCamillo Porta0Medical Oncology, IRCCS San Matteo University Hospital Foundation; Gruppo Italiano di Oncologia Nefrologica (GION, Italian Nephro-Oncology Group), PaviaDespite being the very first molecular targeted agents registered for the treatment of advanced kidney cancer (in the post-cytokines setting), Sorafenib seemed to lose its momentum as a credible first-line treatment option, when it proved not to be superior to Interferon within a randomized phase II trial...http://www.oncologyreviews.org/index.php/or/article/view/10 |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Camillo Porta |
| spellingShingle |
Camillo Porta Sorafenib tosylate for advanced kidney cancer: lucky loser and magic box at the same time Oncology Reviews |
| author_facet |
Camillo Porta |
| author_sort |
Camillo Porta |
| title |
Sorafenib tosylate for advanced kidney cancer: lucky loser and magic box at the same time |
| title_short |
Sorafenib tosylate for advanced kidney cancer: lucky loser and magic box at the same time |
| title_full |
Sorafenib tosylate for advanced kidney cancer: lucky loser and magic box at the same time |
| title_fullStr |
Sorafenib tosylate for advanced kidney cancer: lucky loser and magic box at the same time |
| title_full_unstemmed |
Sorafenib tosylate for advanced kidney cancer: lucky loser and magic box at the same time |
| title_sort |
sorafenib tosylate for advanced kidney cancer: lucky loser and magic box at the same time |
| publisher |
PAGEPress Publications |
| series |
Oncology Reviews |
| issn |
1970-5557 1970-5565 |
| publishDate |
2011-09-01 |
| description |
Despite being the very first molecular targeted agents registered for the treatment of advanced kidney cancer (in the post-cytokines setting), Sorafenib seemed to lose its momentum as a credible first-line treatment option, when it proved not to be superior to Interferon within a randomized phase II trial... |
| url |
http://www.oncologyreviews.org/index.php/or/article/view/10 |
| work_keys_str_mv |
AT camilloporta sorafenibtosylateforadvancedkidneycancerluckyloserandmagicboxatthesametime |
| _version_ |
1724852336570925056 |